Complementary and alternative therapies for the management of dyslipidemia

Annals of Pharmacotherapy

Volumn 40, Issue 11, 2006, Pages 1984-1992

  Nies, Leslie K ^a,b   Cymbala, Alicia A ^a   Kasten, Sheila L ^a,b   Lamprecht, Donald G ^a,b   Olson, Kari L ^a,b  

^a KAISER PERMANENTE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Alternative therapy; Dyslipidemia; Natural medicine

Indexed keywords

ALPHA CAROTENE; BETA CAROTENE; EZETIMIBE; GARLIC EXTRACT; GUGGULSTERONE; ISPAGULA; MONACOLIN J; MONOUNSATURATED FATTY ACID; OMEGA 3 FATTY ACID; POLICOSANOL; SIMVASTATIN; SOYBEAN PROTEIN; STANOL ESTER; STEROL DERIVATIVE; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ALMOND; ALTERNATIVE MEDICINE; BLOATING; BULIMIA; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DYSLIPIDEMIA; DYSPEPSIA; FLATULENCE; GARLIC; GASTROINTESTINAL SYMPTOM; HALITOSIS; HEARTBURN; HUMAN; HYPERTRIGLYCERIDEMIA; INSOMNIA; LINSEED; MEDLINE; META ANALYSIS; NAUSEA; ODOR; PLANT FIBER; POLYURIA; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RICE; SIDE EFFECT; SOYBEAN; SYSTEMATIC REVIEW; TASTE DISORDER; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

COMPLEMENTARY THERAPIES; DYSLIPIDEMIAS; HUMANS; META-ANALYSIS; PHYTOSTEROLS; PHYTOTHERAPY;

EID: 33751010229     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H040     Document Type: Review

References (90)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
2. Bruno JJ, Ellis JJ. Herbal use among US elderly: 2002 National Health Interview Survey. Ann Pharmacother 2005;39:643-8. Epub 1 Mar 2005. DOI 10.1345/aph.1E460
3. Kelly JP, Kaufman DW, Kelley K, Rosenberg L, Anderson TE, Mitchell AA. Recent trends in use of herbal and other natural trends. Arch Intern Med 2005;165:281-6.
4. Park Y, Harris WS. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J Lipid Res 2003;44:455-63.
5. Weber P, Raederstorff D. Triglyceride-lowering effect of omega-3 LC-polyunsaturated fatty acids-a review. Nutr Metab Cardiovasc Dis 2000;10:28-37.
6. Harris WS, Ginsberg HN, Arunakul N, et al. Safety and efficacy of Omacorin severe hypertriglyceridemia. J Cardiovasc Risk 1997;4:385-91.
7. Harris WS. n-3 fatty acids and serum lipoprotein: human studies. Am J Clin Nutr 1997;65(suppl):1645S-54S.
8. Kris-Etherton PM, Harris WS, Appel LJ, for the Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids and cardiovascular disease. Circulation 2002;106:2747-57.
9. Contacos C, Barter PJ, Sullivan DR. Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia. Arterioscler Thromb 1993;13:1755-62.
10. Durrington PN, Bhatnagar D, Mackness MI, et al. An omega-3 polyun-saturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart 2001;85:544-8.
11. Nordoy A, Bonaa KH, Nilsen H, Berge RK, Hansen JB, Ingebretsen OC. Effects of simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia. J Intern Med 1998;243:163-70.
12. Davidson MH, Maki KC, Kalkowski J, Schaefer EJ, Torri SA, Drennan KM. Effects of docosahexaenoic acid on serum lipoproteins in patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled trial. J Am Coll Nutr 1997;16:236-43.
13. Connor WE, Prince MJ, Ullmann D, et al. The hypotriglyceridemic effect offish oil in adult-onset diabetes without adverse glucose control. Ann N Y Acad Sci 1993;683:337-40.
14. Friedberg CE, Janssen MJ, Heine RJ, Grobbee DE. Fish oil and glycemic control in diabetes: a meta-analysis. Diabetes Care 1998;21:494-500.
15. Eritsland J. Safety considerations of polyunsaturated fatty acids. Am J Clin Nutr 2000;71(suppl):197S-201S.
16. Law M. Plant sterol and stanol margarines and health. BMJ 2000;320:861-4.
17. Chen JT, Wesley R, Shamburek RD, Pucino F, Csako G. Meta-analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol. Pharmacotherapy 2005;25:171-83.
18. Devaraj S, Jialal I, Vega-Lopez S. Plant sterol-fortified orange juice effectively lowers cholesterol levels in mildly hypercholesterolemic healthy individuals. Arterioscler Thromb Vasc Biol 2004;24:e25-e28. DOI 10.1161/01.ATV.0000120784.08823.99
19. Lau VW, Journoud M, Jones PJ. Plant sterols are efficacious in lowering plasma LDL and non-HDL cholesterol in hypercholesterolemic type 2 diabetic and nondiabetic persons. Am J Clin Nutr 2005;81:1351-8.
20. Blair SN, Capuzzi DM, Gottlieb SO, Nguyen T, Morgan JM, Cater NB. Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy. Am J Cardiol 2000;86:46-52.
21. Hallikainen MA, Sarkkinen ES, Uusitupa MI. Plant stanol esters affect serum cholesterol concentrations of hypercholesterolemic men and women in a dose-dependent manner. J Nutr 2000;130:767-76.
22. Plat J, van Onselen EN, van Heugten MM, Mensink RP. Effects on serum lipids, lipoproteins and fat soluble antioxidant concentrations of consumption frequency of margarines and shortenings enriched with plant stanol esters. Eur J Clin Nutr 2000;54:671-7.
23. Sudhop T, Lutjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002;106:1943-8.
24. Jakulj L, Trip MD, Sudhop T, von Bergmann K, Kastelein JJ, Vissers MN. Inhibition of cholesterol absorption by the combination of dietary plant sterols and ezetimibe: effects on plasma lipid levels. J Lipid Res 2005;46:2696-8.
25. Fernandez ML. Soluble fiber and nondigestible carbohydrate effects on plasma lipids and cardiovascular risk. Curr Opin Lipidol 2001;12:35-40.
26. Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr 1999;69:30-42.
27. Romero AL, Romero JE, Galaviz S, Fernandez ML. Cookies enriched with psyllium or oat bran lower plasma LDL cholesterol in normal and hypercholesterolemic men from Northern Mexico. J Am Coll Nutr 1998;17:601-8.
28. Behall KM, Scholfield DJ, Hallfrisch J. Lipids significantly reduced by diets containing barley in moderately hypercholesterolemic men. J Am Coll Nutr 2004;23:55-62.
29. Anderson JW, Allgood LD, Lawrence A, et al. Cholesterol-lowering effects of psyllium intake adjunctive to diet therapy in men and women with hypercholesterolemia: meta-analysis of 8 controlled trials. Am J Clin Nutr 2000;71:472-9.
30. Moreyra AE, Wilson AC, Koraym A. Effect of combining psyllium fiber with simvastatin in lowering cholesterol. Arch Intern Med 2005;165:1161-6.
31. Erdman JW. Soy protein and cardiovascular disease: a statement for healthcare professionals from the nutrition committee of the AHA. Circulation 2000;102:2555-9.
32. Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 1995;333:276-82.
33. Zhan S, Ho SC. Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile. Am J Clin Nutr 2005;81:397-408.
34. Zhuo X, Melby MK, Watanabe S. Soy isoflavone intake lowers serum LDL cholesterol: a meta-analysis of 8 randomized controlled trials in humans. J Nutr 2004;134:2395-400.
35. Weggemans RM, Trautwein EA. Relation between soy-associated isoflavones and LDL and HDL cholesterol concentrations in humans: a meta-analysis. Eur J Clin Nutr 2003;57:940-6.
36. Høie L, Graubaum H, Harde A, Gruenwald J, Wernecke K. Lipid-lowering effect of 2 dosages of a soy protein supplement in hypercholesterolemia. Adv Ther 2005;22:175-86.
37. West GS, Hilpert KF, Juturu V, et al. Effects of including soy protein in a blood cholesterol-lowering diet on markers of cardiac risk in men and in postmenopausal women with and without hormone replacement. J Womens Health 2005;14:253-62.
38. Wang Y, Jones PJH, Ausman LM, Lichtenstein AH. Soy protein reduces triglyceride levels and triglyceride fatty acid fractional synthesis rate in hypercholesterolemic subjects. Atherosclerosis 2004;173:269-75.
39. Hermansen K, Hansen B, Jacobsen R, et al. Effects of soy supplementation on blood lipids and arterial function in hypercholesterolemic subjects. Eur J Clin Nutr 2005;59:843-50.
40. Blum A, Lang N, Vigder F, et al. Effects of soy protein on endothelium-dependent vasodilatation and lipid profile in postmenopausal women with mild hypercholesterolemia. Clin Invest Med 2003;26:20-6.
41. Yunsheng M, Chiriboga D, Olendzki BC, Nicolosi R, Merriam PA, Ockene IS. Effect of soy protein containing isoflavones on blood lipids in moderately hypercholesterolemic adults: a randomized controlled trial. J Am Coll Nutr 2005;24:275-85.
42. Teede JH, Dalais FS, Kotsopoulos D, Liang YL, Davis S, McGrath BP. Dietary soy has both beneficial and potentially adverse cardiovascular effects: a placebo-controlled study in men and postmenopausal women. J Clin Endocrinol Metab 2001;86:3053-60.
43. Kreijkamp-Kaspers S,Kok L, Grobbee DE, et al. Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women. JAMA 2004;292:65-73.
44. Jellin JM, Gregory BJ, Batz F, et al. Pharmacist's letter/prescriber's letter. Natural Medicine's Comprehensive Database. www.naturaldatabase.com (accessed 2006 Mar 1).
45. FDA approves new health claim for soy protein and coronary heart disease. October 20, 1999. www.fda.gov/bbs/topics/ANSWERS/ANS00980 (accessed 2006 Mar 29).
46. Yeh YY, Liu L. Cholesterol-lowering effect of garlic extracts and organosulfur compounds: human and animal studies. J Nutr 2001;3s:989s-93s.
47. Stevinson C, Pittler MH, Ernst E. Garlic for treating hypercholesterolemia. Ann Intern Med 2000;133:420-9.
48. Ackermann R, Mulrow CD, Ramirez G, Gardner CD, Marbidoni L, Lawrence VA. Garlic shows promise for improving some cardiovascular risk factors. Arch Intern Med 2001;161:813-24.
49. Peleg A, Hershcovici T, Lipa R, Anbar R, Redler M, Beigel Y. Effect of garlic on lipid profile and psychopathologic parameters in people with mild to moderate hypercholesterolemia. Isr Med Assoc J 2003;9:637-40.
50. Satitvipawee P, Rawdaree P, Indrabhakti S, Ratanasuwan T, Getn-gern P, Viwatwongkasem C. No effect of garlic extract supplement on serum lipid levels in hypercholesterolemic subjects. J Med Assoc Thai 2003;86:750-7.
51. Kannar D, Wattanapenpaiboon N, Savige GS, Wahlqvist ML. Hypocholesterolemic effect of an enteric-coated garlic supplement. J Am Coll Nutr 2001;20:225-31.
52. Gardner CD, Chatterjee LM, Carlson JJ. The effect of a garlic preparation on plasma lipid levels in moderately hypercholesterolemic adults. Atherosclerosis 2001;154:213-20.
53. Vaes LP, Chyka PA. Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: nature of the evidence. Ann Pharmacother 2000;34:1478-82. DOI 10.1345/aph.l0031
54. Delgoda R, Westlake AC. Herbal interactions involving cytochrome p450 enzymes: a mini review. Toxicol Rev 2004;23:239-49.
55. Szapary PO, Wolfe ML, Bloedon LT, et al. Guggulipid for the treatment of hypercholesterolemia. JAMA 2003;290:765-72.
56. Singh RB, Niaz MA, Ghosh S. Hypolipidemic and antioxidant effects of Commiphora mukul as an adjunct to dietary therapy in patients with hypercholesterolemia. Cardiovasc Drugs Ther 1994;8:659-64.
57. Nityanand S, Srivastava JS, Asthana OP. Clinical trials with guggulipid. A new hypolipidaemic agent. J Assoc Physicians India 1989;37:323-8.
58. Blanchi A, Cantù P, Firenzuoli F, Mazzanti G, Menniti-Ippolito F, Raschetti R. Rhabdomyolysis caused by Commiphora mukul, a natural lipid-lowering agent. Ann Pharmacother 2004;38:1222-5. Epub 8 Jun 2004. DOI 10.1345/aph.1D486
59. Brobst DE, Ding X, Creech KL, Goodwin B, Kelley B, Staudinger JL. Guggulsterone activates multiple nuclear receptors and induces CYP3A gene expression through the pregnane X receptor. J Pharmacol Exp Ther 2004;310:528-35.
60. Dalvi SS, Nayak VK, Pohujani SM,Desai NK, Kshirsagar NA, Gupta KC. Effect of guggulipid on bioavailability of diltiazem and propranolol. J Assoc Physicians India 1994;42:454-5.
61. Heber D, Lembertas A, Lu QY, Bowerman S, Go VL. An analysis of nine proprietary Chinese red yeast rice dietary supplements: implications of variability in chemical profile and contents. J Altern Complement Med 2001;2:133-9.
62. Heber D, Yip I, Ashley JM, Elashoff DA, Go VL. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 1999;69:231-6.
63. Lin C, Lii T, Lai M. Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia. Eur J Endocrinol 2005;152:679-86.
64. Prasad GV, Wong T, Meliton G, Bhaloo S. Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. Transplantation 2002;74:1200-1.
65. Menendez R, Fernandez SI, Del Rio A, et al. Policosanol inhibits cholesterol biosynthesis and enhances low density lipoprotein processing in cultured human fibroblasts. Biol Res 1994;27:199-203.
66. Menendez R, Amor AM, Gonzales RM, Fraga V, Mas R. Effect of policosanol on the hepatic cholesterol biosynthesis of normocholesterolemic rats. Biol Res 1996;29:253-7.
67. Menendez R, Arruzazabala L, Mas R, et al. Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolemia induced by wheat starch-casein diet. Br J Nutr 1997;77:923-32.
68. Ortensi G, Gladstein J, Valli H, et al. A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia. Curr Ther Res 1997;58:390-401.
69. Crespo N, Illnait J, Mas R, Feraandez L, Fernandez J, Castano G. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus. Int J Clin Pharmacol Res 1999;19:117-27.
70. Castano G, Mas R, Arruzazabala ML, et al. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypereholesterolemic patients. Int J Clin Pharmacol Res 1999;19:105-16.
71. Fernandez JC, Mas R, Castano G, et al. Comparison of the efficacy, safety and tolerability of policosanol versus fluvastatin in elderly hypercholesterolaemic women. Clin Drug Invest 2001;21:103-13.
72. Castano G, Mas R, Gamez R, et al. Concomitant use of policosanol and β-blockers in older patients. Int J Clin Pharm Res 2004;24:65-77.
73. Castano G, Fernandez L, Mas R, et al. Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia. Drugs R D 2005;6:207-19.
74. Lin Y, Rudrum M, van der Wielen RPJ, et al. Wheat germ policosanol failed to lower plasma cholesterol in subjects with normal to mildly elevated cholesterol concentrations. Metabolism 2004;53:1309-14.
75. Castano G, Mas R, Fernandez L, Illnait J, Gamez R, Alvarez E. Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study. Int J Clin Pharmacol Res 2001;21:43-57.
76. Zardoya R, Tula L, Castano G, et al. Effects of policosanol on hypereholesterolemic patients with abnormal serum biochemical indicators of hepatic function. Curr Ther Res 1996;57:568-77.
77. Canetti M, Moreira M, Mas R, et al. A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia. Int J Clin Pharmacol Res 1995;15:159-65.
78. Fernandez L, Mas R, Illnait J, Fernandez JC. Policosanol: results of a postmarketing surveillance study of 27,879 patients. Curr Ther Res Clin Exp 1998;59:717-22.
79. Gouni-Berthold I, Berthold HK. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J 2002;143:356-65.
80. Nash SD, Westpfal M. Cardiovascular benefits of nuts. Am J Cardiol 2005;95:963-5.
81. Sabaté J, Haddad E, Tanzman JS, Jambazian P, Rajaram S. Serum lipid response to the graduated enrichment of a step I diet with almonds: a randomized feeding trial. Am J Clin Nutr 2003;77:1379-84.
82. Jenkins DA, Kendall CC, Marchie A, et al. Dose response of almonds on coronary heart disease risk factors: blood lipids, oxidized low-density lipoproteins, lipoprotein(a), homocysteine, and pulmonary nitric oxide-a randomized controlled, crossover trial. Circulation 2002;106:1327-32.
83. Zambon D, Sabate J, Munoz S, et al. Substituting walnuts for monoun-saturated fat improves serum lipid profile of hypercholesterolemic men and women: a randomized crossover trial. Ann Intern Med 2000;132:538-46.
84. Krauss R, Eckel R, Howard B, et al. AHA dietary guidelines. Circulation 2000;102:2296-311.
85. Cunnane SC, Hamadeh MJ, Liede AC, Thompson LU, Wolever TM, Jenkins DJ. Nutritional attributes of traditional flaxseed in healthy young adults. Am J Clin Nutr 1995;61:62-8.
86. Jenkins DJ, Kendall CW, Garsetti M, et al. Health aspects of partially defatted flaxseed, including effects on serum lipids, oxidative measures, and ex vivo androgen and progestin activity: a controlled crossover trial. Am J Clin Nutr 1999;69:395-402.
87. Lemay A, Dodin S, Kadri N, Jacques H, Forest JC. Flaxseed dietary supplement versus hormone replacement therapy in hypercholesterolemic menopausal women. Obstet Gynecol 2002;100:495-504.
88. Lucas EA, Wild RD, Hammond LJ, et al. Flaxseed improves lipid profile without altering biomarkers of bone metabolism in postmenopausal women. J Clin Endocrinol Metab 2002;87:1527-32.
89. Dodin S, Lemay A, Jacques H, Legare F, Forest JC, Masse B. The effects of flaxseed dietary supplement on lipid profile, bone mineral density, and symptoms in menopausal women: a randomized, double-blind, wheat germ placebo-controlled clinical trial. J Clin Endocrinol Metab 2005;90:1390-7.
90. Micromedex Healthcare Series (electronic version). Thomson Micromedex, Greenwood Village, CO. www.thomsonhc.com (accessed 2006 Mar 6).